41 – 50 of 91
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid concentrations of extracellular matrix proteins in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays : Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS
(
- Contribution to journal › Article
- 2018
-
Mark
Altered structural network organization in cognitively normal individuals with amyloid pathology
(
- Contribution to journal › Article
-
Mark
Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarker levels: Total tau and phosphorylated tau as markers for rate of progression in Alzheimer’s disease.
2018) Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting 2018(
- Contribution to conference › Abstract
- 2017
-
Mark
Preclinical effects of APOE ϵ4 on cerebrospinal fluid Aβ42 concentrations
(
- Contribution to journal › Article